US4356167A
(en)
*
|
1978-01-27 |
1982-10-26 |
Sandoz, Inc. |
Liposome drug delivery systems
|
IT1111367B
(it)
*
|
1978-11-17 |
1986-01-13 |
Serono Ist Farm |
Processo per la preparazione estemporanea di liposomi e liposomi cosi' ottenuti
|
DE3068743D1
(en)
|
1980-01-16 |
1984-08-30 |
Weder Hans G |
Process and dialysis-installation for the preparation of bilayer-vesicles and their use
|
US4302459A
(en)
*
|
1980-03-19 |
1981-11-24 |
The United States Of America As Represented By The Secretary Of The Army |
Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives
|
DE43327T1
(de)
*
|
1980-07-01 |
1983-01-05 |
L'Oreal, 75008 Paris |
Verfahren zur herstellung stabiler dispersionen in einer waessrigen phase von mindestens einer fluessigen, nicht mit wasser mischbaren phase und die entsprechenden dispersionen.
|
EP0047480B1
(en)
*
|
1980-09-05 |
1986-02-05 |
Institut Armand Frappier |
Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
|
US4394372A
(en)
*
|
1980-12-22 |
1983-07-19 |
The Procter & Gamble Company |
Process for making lipid membrane structures
|
GR77320B
(da)
*
|
1980-12-22 |
1984-09-11 |
Procter & Gamble |
|
DE3269389D1
(en)
*
|
1981-08-10 |
1986-04-03 |
Wellcome Found |
Pharmaceutical formulations containing antimony
|
NL193099C
(nl)
*
|
1981-10-30 |
1998-11-03 |
Novo Industri As |
Gestabiliseerde insuline-oplossing.
|
EP0088046B1
(de)
*
|
1982-02-17 |
1987-12-09 |
Ciba-Geigy Ag |
Lipide in wässriger Phase
|
US4416872A
(en)
*
|
1982-03-17 |
1983-11-22 |
The United States Of America As Represented By The Secretary Of The Army |
Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates
|
AU564876B2
(en)
*
|
1982-03-29 |
1987-08-27 |
Liposome Company, Inc., The |
Stable plurilamellar vesicles
|
US4522803A
(en)
*
|
1983-02-04 |
1985-06-11 |
The Liposome Company, Inc. |
Stable plurilamellar vesicles, their preparation and use
|
US5435989A
(en)
|
1982-03-30 |
1995-07-25 |
Vestar, Inc. |
Method of targeting a specific location in a body
|
US5441745A
(en)
*
|
1982-03-30 |
1995-08-15 |
Vestar, Inc. |
Method of delivering micellular particles encapsulating chemotherapeutic agents to tumors in a body
|
US4425334A
(en)
|
1982-04-02 |
1984-01-10 |
The Regents Of The University Of California |
Functional oxygen transport system
|
US4612370A
(en)
*
|
1982-04-02 |
1986-09-16 |
The Regents Of The University Of California |
Lipid-saccharide reaction products
|
US4522811A
(en)
*
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
EP0100964A3
(de)
*
|
1982-07-31 |
1984-06-13 |
Reifenrath, Rainer, Dr. |
Pharmazeutisches Erzeugnis zur Behandlung und Prophylaxe von Infektionen sowie von Husten und obstruktiven Atemwegserkrankungen sowie Verfahren zu seiner Herstellung
|
US4485054A
(en)
*
|
1982-10-04 |
1984-11-27 |
Lipoderm Pharmaceuticals Limited |
Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
|
US4501728A
(en)
*
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
FR2540381B1
(fr)
*
|
1983-02-08 |
1986-05-30 |
Dior Sa Parfums Christian |
Procede pour stimuler la croissance des cellules; composition cosmetique, pharmaceutique et composition complementaire pour milieu de culture cellulaire appliquant ce procede
|
US5387410A
(en)
*
|
1983-03-18 |
1995-02-07 |
Mallinckrodt, Inc. |
Method for enhancing magnetic resonance with compositions containing paramagnetic elements carried by liposomes
|
US4588578A
(en)
*
|
1983-08-08 |
1986-05-13 |
The Liposome Company, Inc. |
Lipid vesicles prepared in a monophase
|
US5186941A
(en)
*
|
1983-05-06 |
1993-02-16 |
Vestar, Inc. |
Vesicle formulation for the controlled release of therapeutic agents
|
WO1995013796A1
(en)
*
|
1993-11-16 |
1995-05-26 |
Depotech Corporation |
Vesicles with controlled release of actives
|
FR2561101B1
(fr)
*
|
1984-03-13 |
1986-10-31 |
Paris Sud Universite |
Procede de preparation de liposomes et liposomes ainsi obtenus
|
US4610868A
(en)
*
|
1984-03-20 |
1986-09-09 |
The Liposome Company, Inc. |
Lipid matrix carriers for use in drug delivery systems
|
US5231112A
(en)
|
1984-04-12 |
1993-07-27 |
The Liposome Company, Inc. |
Compositions containing tris salt of cholesterol hemisuccinate and antifungal
|
US4921706A
(en)
*
|
1984-11-20 |
1990-05-01 |
Massachusetts Institute Of Technology |
Unilamellar lipid vesicles and method for their formation
|
US4857319A
(en)
*
|
1985-01-11 |
1989-08-15 |
The Regents Of The University Of California |
Method for preserving liposomes
|
US4707453A
(en)
*
|
1985-04-05 |
1987-11-17 |
Becton Dickinson And Company |
Vesicle including a metal marker for use in an assay
|
US4698263A
(en)
*
|
1985-05-23 |
1987-10-06 |
Becton Dickinson And Company |
Sac having a marker linked thereto
|
US5409704A
(en)
*
|
1985-06-26 |
1995-04-25 |
The Liposome Company, Inc. |
Liposomes comprising aminoglycoside phosphates and methods of production and use
|
US4861580A
(en)
*
|
1985-10-15 |
1989-08-29 |
The Liposome Company, Inc. |
Composition using salt form of organic acid derivative of alpha-tocopheral
|
US5041278A
(en)
*
|
1985-10-15 |
1991-08-20 |
The Liposome Company, Inc. |
Alpha tocopherol-based vesicles
|
FR2591105B1
(fr)
|
1985-12-11 |
1989-03-24 |
Moet Hennessy Rech |
Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
|
JPH0751496B2
(ja)
*
|
1986-04-02 |
1995-06-05 |
武田薬品工業株式会社 |
リポソ−ムの製造法
|
FR2597345B1
(fr)
*
|
1986-04-22 |
1990-08-03 |
Oreal |
Composition cosmetique ou pharmaceutique a base d'une dispersion aqueuse de spherules lipidiques.
|
US6759057B1
(en)
|
1986-06-12 |
2004-07-06 |
The Liposome Company, Inc. |
Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
|
EP0269720B1
(en)
*
|
1986-06-16 |
1992-02-19 |
The Liposome Company, Inc. |
Induction of asymmetry in vesicles
|
US5252263A
(en)
*
|
1986-06-16 |
1993-10-12 |
The Liposome Company, Inc. |
Induction of asymmetry in vesicles
|
US5204112A
(en)
*
|
1986-06-16 |
1993-04-20 |
The Liposome Company, Inc. |
Induction of asymmetry in vesicles
|
EP0293465B1
(en)
*
|
1986-11-28 |
1992-03-18 |
The Liposome Company, Inc. |
Phospholipid composition
|
US4783220A
(en)
*
|
1986-12-18 |
1988-11-08 |
Xerox Corporation |
Vesicle ink compositions
|
AU609711B2
(en)
*
|
1986-12-23 |
1991-05-09 |
Liposome Company, Inc., The |
Liposome preparation and antibiotic
|
GB8704171D0
(en)
*
|
1987-02-23 |
1987-04-01 |
Clayton Found Res |
Multivesicular liposomes
|
US5723147A
(en)
*
|
1987-02-23 |
1998-03-03 |
Depotech Corporation |
Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
|
US6406713B1
(en)
|
1987-03-05 |
2002-06-18 |
The Liposome Company, Inc. |
Methods of preparing low-toxicity drug-lipid complexes
|
US4963297A
(en)
*
|
1987-12-22 |
1990-10-16 |
The Liposome Company, Inc. |
Spontaneous vesticulation of multilamellar liposomes
|
MX9203808A
(es)
*
|
1987-03-05 |
1992-07-01 |
Liposome Co Inc |
Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
|
US5616334A
(en)
*
|
1987-03-05 |
1997-04-01 |
The Liposome Company, Inc. |
Low toxicity drug-lipid systems
|
US5925375A
(en)
*
|
1987-05-22 |
1999-07-20 |
The Liposome Company, Inc. |
Therapeutic use of multilamellar liposomal prostaglandin formulations
|
MX9203804A
(es)
*
|
1987-10-19 |
1992-07-01 |
Liposome Co Inc |
Sistemas farmaceuticos a base de tocoferol.
|
US4873035A
(en)
*
|
1987-11-25 |
1989-10-10 |
Abbott Laboratories |
Preparation of sized populations of liposomes
|
US5017501A
(en)
*
|
1987-11-25 |
1991-05-21 |
Abbott Laboratories |
Preparation of uniformly sized liposomes encapsulating an aqueous liquid
|
KR900000848B1
(ko)
*
|
1987-12-30 |
1990-02-17 |
태평양화학 주식회사 |
리포좀을 함유한 화장료의 제조방법
|
US5807572A
(en)
*
|
1988-02-18 |
1998-09-15 |
Depotech Corporation |
Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
|
US5013497A
(en)
*
|
1988-03-03 |
1991-05-07 |
Micro-Pak, Inc. |
Method and apparatus for producing lipid vesicles
|
US5948441A
(en)
*
|
1988-03-07 |
1999-09-07 |
The Liposome Company, Inc. |
Method for size separation of particles
|
US5422120A
(en)
*
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
CA1339034C
(en)
*
|
1988-08-22 |
1997-04-01 |
Paul A. Tremblay |
Platinum complexes of single isomer neoalkyl acids
|
US5043165A
(en)
*
|
1988-12-14 |
1991-08-27 |
Liposome Technology, Inc. |
Novel liposome composition for sustained release of steroidal drugs
|
US4906476A
(en)
*
|
1988-12-14 |
1990-03-06 |
Liposome Technology, Inc. |
Novel liposome composition for sustained release of steroidal drugs in lungs
|
ES2072424T3
(es)
|
1989-01-27 |
1995-07-16 |
Immunolytics Inc |
Formula y metodo para el tratamiento de hipertrofias prostaticas benignas.
|
US5116615A
(en)
*
|
1989-01-27 |
1992-05-26 |
Immunolytics, Inc. |
Method for treating benign prostatic hypertrophy
|
US5078986A
(en)
*
|
1989-02-15 |
1992-01-07 |
Mallinckrodt Medical, Inc. |
Method for enhancing magnetic resonance imaging using an image altering agent containing an excess of chelating agent
|
US5100662A
(en)
*
|
1989-08-23 |
1992-03-31 |
The Liposome Company, Inc. |
Steroidal liposomes exhibiting enhanced stability
|
IE904098A1
(en)
*
|
1989-11-13 |
1991-05-22 |
Nova Pharm Corp |
Lipospheres for controlled delivery of substances
|
US5188837A
(en)
*
|
1989-11-13 |
1993-02-23 |
Nova Pharmaceutical Corporation |
Lipsopheres for controlled delivery of substances
|
US5221535A
(en)
*
|
1989-11-13 |
1993-06-22 |
Nova Pharmaceutical Corporation |
Sustained release formulations of insect repellent
|
US5227165A
(en)
*
|
1989-11-13 |
1993-07-13 |
Nova Pharmaceutical Corporation |
Liposphere delivery systems for local anesthetics
|
US6146657A
(en)
*
|
1989-12-22 |
2000-11-14 |
Imarx Pharmaceutical Corp. |
Gas-filled lipid spheres for use in diagnostic and therapeutic applications
|
US5733572A
(en)
*
|
1989-12-22 |
1998-03-31 |
Imarx Pharmaceutical Corp. |
Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
|
US5922304A
(en)
*
|
1989-12-22 |
1999-07-13 |
Imarx Pharmaceutical Corp. |
Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
|
US5705187A
(en)
*
|
1989-12-22 |
1998-01-06 |
Imarx Pharmaceutical Corp. |
Compositions of lipids and stabilizing materials
|
US5469854A
(en)
*
|
1989-12-22 |
1995-11-28 |
Imarx Pharmaceutical Corp. |
Methods of preparing gas-filled liposomes
|
US5776429A
(en)
*
|
1989-12-22 |
1998-07-07 |
Imarx Pharmaceutical Corp. |
Method of preparing gas-filled microspheres using a lyophilized lipids
|
US5656211A
(en)
*
|
1989-12-22 |
1997-08-12 |
Imarx Pharmaceutical Corp. |
Apparatus and method for making gas-filled vesicles of optimal size
|
US5352435A
(en)
*
|
1989-12-22 |
1994-10-04 |
Unger Evan C |
Ionophore containing liposomes for ultrasound imaging
|
US5585112A
(en)
*
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
US6551576B1
(en)
|
1989-12-22 |
2003-04-22 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Container with multi-phase composition for use in diagnostic and therapeutic applications
|
US5305757A
(en)
*
|
1989-12-22 |
1994-04-26 |
Unger Evan C |
Gas filled liposomes and their use as ultrasonic contrast agents
|
US5580575A
(en)
*
|
1989-12-22 |
1996-12-03 |
Imarx Pharmaceutical Corp. |
Therapeutic drug delivery systems
|
US6001335A
(en)
*
|
1989-12-22 |
1999-12-14 |
Imarx Pharmaceutical Corp. |
Contrasting agents for ultrasonic imaging and methods for preparing the same
|
US6088613A
(en)
|
1989-12-22 |
2000-07-11 |
Imarx Pharmaceutical Corp. |
Method of magnetic resonance focused surgical and therapeutic ultrasound
|
US5542935A
(en)
*
|
1989-12-22 |
1996-08-06 |
Imarx Pharmaceutical Corp. |
Therapeutic delivery systems related applications
|
US5773024A
(en)
*
|
1989-12-22 |
1998-06-30 |
Imarx Pharmaceutical Corp. |
Container with multi-phase composition for use in diagnostic and therapeutic applications
|
US20020150539A1
(en)
|
1989-12-22 |
2002-10-17 |
Unger Evan C. |
Ultrasound imaging and treatment
|
ZA911974B
(en)
*
|
1990-03-21 |
1994-08-22 |
Res Dev Foundation |
Heterovesicular liposomes
|
US6613306B1
(en)
|
1990-04-02 |
2003-09-02 |
Bracco International B.V. |
Ultrasound contrast agents and methods of making and using them
|
US20040208826A1
(en)
*
|
1990-04-02 |
2004-10-21 |
Bracco International B.V. |
Ultrasound contrast agents and methods of making and using them
|
US6989141B2
(en)
*
|
1990-05-18 |
2006-01-24 |
Bracco International B.V. |
Ultrasound contrast agents and methods of making and using them
|
IN172208B
(da)
*
|
1990-04-02 |
1993-05-01 |
Sint Sa |
|
US20010024638A1
(en)
*
|
1992-11-02 |
2001-09-27 |
Michel Schneider |
Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof
|
US5578292A
(en)
|
1991-11-20 |
1996-11-26 |
Bracco International B.V. |
Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
|
US5445813A
(en)
*
|
1992-11-02 |
1995-08-29 |
Bracco International B.V. |
Stable microbubble suspensions as enhancement agents for ultrasound echography
|
US7083778B2
(en)
*
|
1991-05-03 |
2006-08-01 |
Bracco International B.V. |
Ultrasound contrast agents and methods of making and using them
|
USRE39146E1
(en)
|
1990-04-02 |
2006-06-27 |
Bracco International B.V. |
Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
|
US20030194376A1
(en)
*
|
1990-05-18 |
2003-10-16 |
Bracco International B.V. |
Ultrasound contrast agents and methods of making and using them
|
AU636481B2
(en)
*
|
1990-05-18 |
1993-04-29 |
Bracco International B.V. |
Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
|
DE69120089T2
(de)
*
|
1990-07-31 |
1996-12-12 |
Liposome Co Inc |
Anhäufung von aminosäuren und peptiden in liposomen
|
AU8443591A
(en)
*
|
1990-09-06 |
1992-03-30 |
S.C. Johnson & Son, Inc. |
Stabilized liposome process and compositions containing them
|
US5205290A
(en)
*
|
1991-04-05 |
1993-04-27 |
Unger Evan C |
Low density microspheres and their use as contrast agents for computed tomography
|
US5874062A
(en)
*
|
1991-04-05 |
1999-02-23 |
Imarx Pharmaceutical Corp. |
Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
|
US5567432A
(en)
*
|
1991-08-02 |
1996-10-22 |
Lau; John R. |
Masking of liposomes from RES recognition
|
IL104084A
(en)
|
1992-01-24 |
1996-09-12 |
Bracco Int Bv |
Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
|
US5455044A
(en)
*
|
1993-05-14 |
1995-10-03 |
Depotech Corporation |
Method for treating neurological disorders
|
DE1118326T1
(de)
*
|
1993-05-21 |
2002-04-18 |
The Liposome Co., Inc. |
Reduzierung von durch Liposomen induzierten physiologischen Gegenreaktionen
|
US7083572B2
(en)
|
1993-11-30 |
2006-08-01 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Therapeutic delivery systems
|
CA2154867C
(en)
|
1993-12-15 |
2007-05-29 |
Feng Yan |
Gas mixtures useful as ultrasound contrast media
|
DE69530914T2
(de)
*
|
1994-02-17 |
2004-03-11 |
New York Blood Center, Inc. |
Biologische bioadhäsive präparate, die fibrinkleber und liposomen enthalten, verfahren für ihre herstellung und verwendung
|
US5736121A
(en)
*
|
1994-05-23 |
1998-04-07 |
Imarx Pharmaceutical Corp. |
Stabilized homogenous suspensions as computed tomography contrast agents
|
US7091008B1
(en)
*
|
1994-07-01 |
2006-08-15 |
The Board Of Regents Of The University Of Oklahoma |
Hyaluronan synthase genes and expression thereof in Bacillus hosts
|
US6951743B2
(en)
|
1997-10-31 |
2005-10-04 |
University Of Oklahoma Board Of Regents |
Hyaluronan synthase genes and expression thereof in bacillus hosts
|
US6455304B1
(en)
*
|
1994-07-01 |
2002-09-24 |
The Board Of Regents Of The University Of Oklahoma |
Hyaluronate synthase gene and uses thereof
|
US5993850A
(en)
*
|
1994-09-13 |
1999-11-30 |
Skyepharma Inc. |
Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
|
US6743779B1
(en)
|
1994-11-29 |
2004-06-01 |
Imarx Pharmaceutical Corp. |
Methods for delivering compounds into a cell
|
US5830430A
(en)
*
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
US5800833A
(en)
*
|
1995-02-27 |
1998-09-01 |
University Of British Columbia |
Method for loading lipid vesicles
|
US5824638A
(en)
*
|
1995-05-22 |
1998-10-20 |
Shire Laboratories, Inc. |
Oral insulin delivery
|
US5997898A
(en)
*
|
1995-06-06 |
1999-12-07 |
Imarx Pharmaceutical Corp. |
Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
|
US6033645A
(en)
*
|
1996-06-19 |
2000-03-07 |
Unger; Evan C. |
Methods for diagnostic imaging by regulating the administration rate of a contrast agent
|
US6139819A
(en)
*
|
1995-06-07 |
2000-10-31 |
Imarx Pharmaceutical Corp. |
Targeted contrast agents for diagnostic and therapeutic use
|
US6521211B1
(en)
|
1995-06-07 |
2003-02-18 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Methods of imaging and treatment with targeted compositions
|
US6231834B1
(en)
|
1995-06-07 |
2001-05-15 |
Imarx Pharmaceutical Corp. |
Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
|
AU6485496A
(en)
|
1995-07-14 |
1997-02-18 |
Glycotech Corp. |
Compounds and methods for treatment of egf receptor associated cancers and purification of the egf receptor
|
US5931809A
(en)
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
US6022500A
(en)
*
|
1995-09-27 |
2000-02-08 |
The United States Of America As Represented By The Secretary Of The Army |
Polymer encapsulation and polymer microsphere composites
|
US6447800B2
(en)
|
1996-01-18 |
2002-09-10 |
The University Of British Columbia |
Method of loading preformed liposomes using ethanol
|
US6143287A
(en)
*
|
1996-02-27 |
2000-11-07 |
New York Blood Center, Inc. |
Method and composition for hair removal
|
DE69736981D1
(de)
|
1996-05-01 |
2007-01-04 |
Imarx Pharmaceutical Corp |
In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
|
US6414139B1
(en)
|
1996-09-03 |
2002-07-02 |
Imarx Therapeutics, Inc. |
Silicon amphiphilic compounds and the use thereof
|
PT977597E
(pt)
*
|
1996-09-11 |
2003-06-30 |
Imarx Pharmaceutical Corp |
Metodos melhorados para imagiologia de diagnosticoutilizando um agente de contraste e um vasodil atador
|
US5846517A
(en)
*
|
1996-09-11 |
1998-12-08 |
Imarx Pharmaceutical Corp. |
Methods for diagnostic imaging using a renal contrast agent and a vasodilator
|
US5997899A
(en)
|
1996-10-01 |
1999-12-07 |
Skyepharma Inc. |
Method for producing liposomes with increased percent of compound encapsulated
|
US5891467A
(en)
|
1997-01-31 |
1999-04-06 |
Depotech Corporation |
Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
|
US6090800A
(en)
*
|
1997-05-06 |
2000-07-18 |
Imarx Pharmaceutical Corp. |
Lipid soluble steroid prodrugs
|
US6143276A
(en)
*
|
1997-03-21 |
2000-11-07 |
Imarx Pharmaceutical Corp. |
Methods for delivering bioactive agents to regions of elevated temperatures
|
US6537246B1
(en)
|
1997-06-18 |
2003-03-25 |
Imarx Therapeutics, Inc. |
Oxygen delivery agents and uses for the same
|
US6120751A
(en)
|
1997-03-21 |
2000-09-19 |
Imarx Pharmaceutical Corp. |
Charged lipids and uses for the same
|
US7452551B1
(en)
|
2000-10-30 |
2008-11-18 |
Imarx Therapeutics, Inc. |
Targeted compositions for diagnostic and therapeutic use
|
US6416740B1
(en)
|
1997-05-13 |
2002-07-09 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Acoustically active drug delivery systems
|
EP2113247A3
(en)
|
1997-05-14 |
2010-05-05 |
The University Of British Columbia |
High efficiency encapsulation of nucleic acids in lipid vesicles
|
WO1998051278A2
(en)
*
|
1997-05-14 |
1998-11-19 |
Inex Pharmaceuticals Corporation |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
CA2296056A1
(en)
*
|
1997-07-10 |
1999-01-21 |
Keith Baker |
Methods for universally distributing therapeutic agents to the brain
|
US6306432B1
(en)
|
1997-09-08 |
2001-10-23 |
Chiron Corporation |
High and low load formulations of IGF-I in multivesicular liposomes
|
US6548047B1
(en)
|
1997-09-15 |
2003-04-15 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Thermal preactivation of gaseous precursor filled compositions
|
JP4467789B2
(ja)
|
1997-09-18 |
2010-05-26 |
パシラ ファーマシューティカルズ インコーポレーテッド |
持続放出性リポソーム麻酔組成物
|
EP1025211B1
(en)
*
|
1997-10-31 |
2004-12-15 |
The Board of Regents of The University of Oklahoma |
Hyaluronan synthase gene and uses thereof
|
CN101113436B
(zh)
*
|
1997-10-31 |
2013-02-06 |
俄克拉何马大学董事会 |
透明质酸合酶基因及其应用
|
IL135989A0
(en)
*
|
1997-11-14 |
2001-05-20 |
Skyepharma Inc |
Processes for the production of multivesicular liposomes
|
US6123923A
(en)
*
|
1997-12-18 |
2000-09-26 |
Imarx Pharmaceutical Corp. |
Optoacoustic contrast agents and methods for their use
|
US20010003580A1
(en)
|
1998-01-14 |
2001-06-14 |
Poh K. Hui |
Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
|
US6727079B1
(en)
*
|
1998-02-25 |
2004-04-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
|
US20060188966A1
(en)
*
|
1998-04-02 |
2006-08-24 |
Deangelis Paul L |
Natural, chimeric and hybrid glycosaminoglycan polymers and methods of making and using same
|
US20080108110A1
(en)
*
|
1998-04-02 |
2008-05-08 |
Deangelis Paul L |
Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
|
US7223571B2
(en)
*
|
1998-04-02 |
2007-05-29 |
The Board Of Regents Of The Universtiy Of Oklahoma |
Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
|
US6987023B2
(en)
*
|
1998-04-02 |
2006-01-17 |
The Board Of Regents Of The University Of Oklahoma |
DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use
|
US7169410B1
(en)
|
1998-05-19 |
2007-01-30 |
Sdg, Inc. |
Targeted liposomal drug delivery system
|
US7094581B2
(en)
*
|
1998-10-26 |
2006-08-22 |
The Board Of Regents Of The University Of Oklahoma |
Hyaluronan synthases and methods of making and using same
|
US6992081B2
(en)
|
2000-03-23 |
2006-01-31 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
WO2001070672A2
(en)
|
2000-03-23 |
2001-09-27 |
Elan Pharmaceuticals, Inc. |
Compounds and methods to treat alzheimer's disease
|
US20050287638A1
(en)
*
|
2000-04-25 |
2005-12-29 |
Weigel Paul H |
Hyaluronan receptor for endocytosis, variants thereof, and methods of making and using same
|
PE20020276A1
(es)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
|
US6846813B2
(en)
*
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
ATE314343T1
(de)
*
|
2000-06-30 |
2006-01-15 |
Elan Pharm Inc |
Verbindungen zur behandlung der alzheimerischen krankheit
|
US20030096864A1
(en)
*
|
2000-06-30 |
2003-05-22 |
Fang Lawrence Y. |
Compounds to treat alzheimer's disease
|
ATE413164T1
(de)
*
|
2000-11-09 |
2008-11-15 |
Neopharm Inc |
Sn-38-lipidkomplexe und verfahren zu ihrer verwendung
|
US20110301569A1
(en)
|
2001-01-20 |
2011-12-08 |
Gordon Wayne Dyer |
Methods and apparatus for the CVCS
|
AU2002258603A1
(en)
*
|
2001-03-23 |
2002-10-15 |
University Of Michigan |
Method of inhibiting cancerous cell proliferation using ras mutants of gdp-bound conformation
|
WO2003030864A1
(en)
*
|
2001-05-29 |
2003-04-17 |
Neopharm, Inc. |
Liposomal formulation of irinotecan
|
MXPA04000140A
(es)
*
|
2001-06-27 |
2004-06-03 |
Elan Pharm Inc |
Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer.
|
US20030068361A1
(en)
*
|
2001-10-09 |
2003-04-10 |
Rimona Margalit |
Liposome-encapsulated insulin formulations
|
BRPI0105509B8
(pt)
*
|
2001-11-05 |
2021-05-25 |
Univ Minas Gerais |
formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
|
EP1441763A2
(en)
*
|
2001-11-07 |
2004-08-04 |
Inex Pharmaceuticals Corp. |
Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
|
US7476400B2
(en)
*
|
2001-11-13 |
2009-01-13 |
Ferndale Ip, Inc. |
High-concentration lidocaine compositions and methods for their preparation
|
US20070020737A1
(en)
*
|
2001-12-03 |
2007-01-25 |
Pummill Philip E |
Hyaluronan synthases and methods of making and using same
|
US20030134423A1
(en)
*
|
2002-01-04 |
2003-07-17 |
Chu Yong Liang |
Compounds for delivering substances into cells
|
AU2003205048B2
(en)
*
|
2002-01-09 |
2009-02-26 |
Transave, Inc. |
Efficient liposomal encapsulation
|
US20030180348A1
(en)
*
|
2002-03-22 |
2003-09-25 |
Levinson R. Saul |
Transcellular drug delivery system
|
US20040009943A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Pathogen vaccines and methods for using the same
|
US20040013649A1
(en)
*
|
2002-05-10 |
2004-01-22 |
Inex Pharmaceuticals Corporation |
Cancer vaccines and methods of using the same
|
US20060030578A1
(en)
*
|
2002-08-20 |
2006-02-09 |
Neopharm, Inc. |
Pharmaceutically active lipid based formulation of irinotecan
|
AU2003296897A1
(en)
*
|
2002-08-20 |
2004-05-04 |
Neopharm, Inc. |
Pharmaceutical formulations of camptothecine derivatives
|
CN1747738B
(zh)
|
2002-10-29 |
2010-11-24 |
川塞夫有限公司 |
缓释抗感染剂
|
EP1599183A2
(en)
*
|
2002-11-26 |
2005-11-30 |
Gilead Sciences, Inc. |
Method of drug loading in liposomes by gradient
|
US6866856B2
(en)
*
|
2002-12-31 |
2005-03-15 |
Avon Products, Inc. |
Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
|
US20070248541A1
(en)
*
|
2003-12-01 |
2007-10-25 |
Mitsubishi Pharma Corporation |
Liposome
|
US7504385B2
(en)
*
|
2003-12-17 |
2009-03-17 |
Avon Products, Inc. |
si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation
|
US8022279B2
(en)
|
2004-04-22 |
2011-09-20 |
Celator Pharmaceuticals, Inc. |
Liposomal formulations of anthracycline agents and cytidine analogs
|
JP2008506780A
(ja)
|
2004-07-19 |
2008-03-06 |
セレーター ファーマスーティカルズ、インク. |
活性剤放出のための粒子状構築物
|
WO2006052767A2
(en)
|
2004-11-05 |
2006-05-18 |
Inex Pharmaceuticals Corporation |
Compositions and methods for stabilizing liposomal camptothecin formulations
|
KR100651728B1
(ko)
*
|
2004-11-10 |
2006-12-06 |
한국전자통신연구원 |
정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
|
US9944713B2
(en)
|
2004-11-24 |
2018-04-17 |
Medicinal Bioconvergence Research Center |
Antibody specific to the AIMP2-DX2
|
US7459529B2
(en)
|
2004-11-24 |
2008-12-02 |
Seoul National University Industry Foundation |
AIMP2-DX2 and its uses
|
JP5593030B2
(ja)
|
2004-12-20 |
2014-09-17 |
オーストラリアン ニュークリア サイエンス アンド テクノロジー オーガニゼーション |
生物学的物質の調節放出
|
AU2005318928B2
(en)
*
|
2004-12-20 |
2010-06-03 |
Australian Nuclear Science & Technology Organisation |
Controlled release of biological entities
|
KR101340494B1
(ko)
|
2005-06-17 |
2013-12-11 |
오스트레일리언뉴클리어사이언스앤드테크놀로지오거나이제이션 |
방출 가능한 도펀트를 함유한 입자
|
BRPI0612754A2
(pt)
*
|
2005-06-17 |
2010-11-30 |
Australian Nuclear Science Tec |
partìculas tendo material hidrofóbico nelas
|
AU2006257726B2
(en)
*
|
2005-06-17 |
2010-09-09 |
Australian Nuclear Science And Technology Organisation |
Particles having hydrophobic material therein
|
AU2006257727B2
(en)
*
|
2005-06-17 |
2010-09-09 |
Encap Hive Pty Ltd |
Particles comprising a releasable dopant therein
|
WO2007032225A1
(ja)
*
|
2005-09-15 |
2007-03-22 |
Kyoto University |
リポソーム、リポソームの製造方法及び微小反応空間内での反応制御方法
|
WO2007051303A1
(en)
|
2005-11-02 |
2007-05-10 |
Protiva Biotherapeutics, Inc. |
MODIFIED siRNA MOLECULES AND USES THEREOF
|
US9107824B2
(en)
|
2005-11-08 |
2015-08-18 |
Insmed Incorporated |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
WO2007070705A2
(en)
*
|
2005-12-15 |
2007-06-21 |
The Trustees Of The University Of Pennsylvania |
Cationic lipid-mediated vectors
|
US20080094573A1
(en)
*
|
2006-04-04 |
2008-04-24 |
Vermette Patrick |
Surface-modified materials, such as contact lenses, methods and kits for their preparation, and uses thereof
|
JP5502480B2
(ja)
|
2006-09-18 |
2014-05-28 |
コンピュゲン エルティーディー. |
生物活性ペプチド及びその使用方法
|
WO2008130373A2
(en)
|
2006-10-03 |
2008-10-30 |
The Board Of Regents Of The University Of Oklahoma |
Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
|
EP2155165A1
(en)
*
|
2007-04-20 |
2010-02-24 |
BioCure, Inc. |
Drug delivery vehicle containing vesicles in a hydrogel base
|
US8492329B2
(en)
|
2007-07-12 |
2013-07-23 |
Compugen Ltd. |
Bioactive peptides and methods of using same
|
ITRM20070394A1
(it)
*
|
2007-07-16 |
2009-01-17 |
Uni Cattolica Del Sacro Cuo Re |
Liposomi asimmetrici e loro usi in campo medico.
|
ES2550759T3
(es)
|
2007-08-17 |
2015-11-12 |
Celator Pharmaceuticals, Inc. |
Formulaciones farmacológicas de platino mejoradas
|
EP4074344A1
(en)
|
2007-12-04 |
2022-10-19 |
Arbutus Biopharma Corporation |
Targeting lipids
|
EP2231190B1
(en)
*
|
2007-12-06 |
2012-09-26 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Particulate drug carriers as desensitizing agents
|
ES2916498T3
(es)
|
2007-12-06 |
2022-07-01 |
Genalyte Inc |
Método para identificar una secuencia de nucleótidos en una especie desconocida de ácido nucleico; y dispositivo para llevar a cabo el método
|
CA2710713C
(en)
|
2007-12-27 |
2017-09-19 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
EP3100718B1
(en)
|
2008-01-02 |
2019-11-27 |
Arbutus Biopharma Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
AU2009236219B8
(en)
|
2008-04-15 |
2015-06-25 |
Arbutus Biopharma Corporation |
Silencing of CSN5 gene expression using interfering RNA
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
CN102149398B
(zh)
|
2008-09-11 |
2013-12-04 |
I·B·R·以色列生物科技研究有限公司 |
雪片莲属鳞茎提取物及其用途
|
PL2350043T3
(pl)
|
2008-10-09 |
2014-09-30 |
Tekmira Pharmaceuticals Corp |
Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych
|
WO2010062627A2
(en)
|
2008-10-27 |
2010-06-03 |
Genalyte Inc. |
Biosensors based on optical probing and sensing
|
EP3808177A1
(en)
|
2008-11-10 |
2021-04-21 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
CA3036963A1
(en)
|
2009-01-29 |
2010-08-05 |
Arbutus Biopharma Corporation |
Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
|
CN102316852A
(zh)
|
2009-02-11 |
2012-01-11 |
丽卡实验有限公司 |
脂质胞二磷胆碱注射液
|
US20100267806A1
(en)
|
2009-03-12 |
2010-10-21 |
David Bumcrot |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
JP5487666B2
(ja)
*
|
2009-03-23 |
2014-05-07 |
コニカミノルタ株式会社 |
内水相を固定化することを特徴とするリポソームの製造方法
|
EP2416760A4
(en)
|
2009-05-05 |
2014-01-22 |
Tekmira Pharmaceuticals Corp |
LIPID COMPOSITIONS
|
JP5889783B2
(ja)
|
2009-05-05 |
2016-03-22 |
テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation |
免疫細胞へオリゴヌクレオチドを送達する方法
|
PL3431076T3
(pl)
|
2009-06-10 |
2022-01-31 |
Arbutus Biopharma Corporation |
Ulepszona formulacja lipidowa
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
FR2948035B1
(fr)
*
|
2009-07-20 |
2015-04-24 |
Centre Nat Rech Scient |
Procede de fabrication de capsules, capsules ainsi obtenues et utilisation desdites capsules
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
WO2011020023A2
(en)
|
2009-08-14 |
2011-02-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
EP2480668A2
(en)
|
2009-09-23 |
2012-08-01 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing genes expressed in cancer
|
WO2011056682A1
(en)
|
2009-10-27 |
2011-05-12 |
The University Of British Columbia |
Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids
|
CA2783372C
(en)
|
2009-12-07 |
2019-07-16 |
Muthiah Manoharan |
Compositions for nucleic acid delivery
|
AU2010330814B2
(en)
|
2009-12-18 |
2017-01-12 |
Acuitas Therapeutics Inc. |
Methods and compositions for delivery of nucleic acids
|
EP2569276B1
(en)
|
2010-05-12 |
2021-02-24 |
Arbutus Biopharma Corporation |
Novel cationic lipids and methods of use thereof
|
US10077232B2
(en)
|
2010-05-12 |
2018-09-18 |
Arbutus Biopharma Corporation |
Cyclic cationic lipids and methods of use
|
KR20190039347A
(ko)
|
2010-06-03 |
2019-04-10 |
알닐람 파마슈티칼스 인코포레이티드 |
활성제의 전달을 위한 생분해성 지질
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US9921165B2
(en)
|
2010-11-05 |
2018-03-20 |
Genalyte, Inc. |
Optical analyte detection systems and methods of use
|
WO2012064429A2
(en)
|
2010-11-09 |
2012-05-18 |
The Regents Of The University Of California |
Skin permeating and cell entering (space) peptides and methods of use thereof
|
EP3202760B1
(en)
|
2011-01-11 |
2019-08-21 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
JP2014510045A
(ja)
|
2011-02-08 |
2014-04-24 |
ハロザイム インコーポレイテッド |
ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
|
WO2013004234A2
(en)
|
2011-07-04 |
2013-01-10 |
Statens Serum Institut |
Methods for producing liposomes
|
CA2849476A1
(en)
|
2011-09-27 |
2013-04-04 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
WO2013075132A1
(en)
|
2011-11-17 |
2013-05-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Therapeutic rna switches compositions and methods of use
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
EP2606897A1
(en)
|
2011-12-22 |
2013-06-26 |
Laboratorios Del. Dr. Esteve, S.A. |
Methods and compositions for the treatment of diseases caused by enveloped viruses
|
KR102075810B1
(ko)
|
2012-02-24 |
2020-02-10 |
아뷰터스 바이오파마 코포레이션 |
트리알킬 양이온성 지질 및 그의 사용 방법
|
EP3907506A1
(en)
|
2012-03-12 |
2021-11-10 |
The Board of Trustees of the University of Illinois |
Optical analyte detection systems with magnetic enhancement and methods of their use
|
EP2666456A1
(en)
|
2012-05-21 |
2013-11-27 |
Natura Bisse International, S.A. |
Cometic compositions comprising magnetosomes and uses thereof
|
EP2892524B1
(en)
|
2012-09-04 |
2020-11-25 |
Eleison Pharmaceuticals, LLC |
Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
|
EP3677567A1
(en)
|
2013-07-23 |
2020-07-08 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger rna
|
KR101465365B1
(ko)
*
|
2013-10-15 |
2014-11-25 |
성균관대학교산학협력단 |
리포좀 내 고분자 충진된 다중 기능 복합 입자체 및 이의 제조방법
|
KR101638156B1
(ko)
|
2013-10-29 |
2016-07-08 |
가톨릭대학교 산학협력단 |
C형 간염 바이러스 감염 질환의 예방 또는 치료용 약학 조성물
|
HUE043847T2
(hu)
|
2014-08-28 |
2019-09-30 |
Halozyme Inc |
Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
|
SG11201702662UA
(en)
|
2014-10-02 |
2017-04-27 |
Protiva Biotherapeutics Inc |
Compositions and methods for silencing hepatitis b virus gene expression
|
JP2018504380A
(ja)
|
2014-12-18 |
2018-02-15 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Reversir(商標)化合物
|
JP6316182B2
(ja)
*
|
2014-12-19 |
2018-04-25 |
富士フイルム株式会社 |
リポソームの製造方法及びリポソーム製造装置
|
IL296875A
(en)
|
2014-12-31 |
2022-12-01 |
Lantheus Medical Imaging Inc |
Fat-wrapped gas microsphere preparations and related methods
|
US9931298B2
(en)
|
2015-05-26 |
2018-04-03 |
Comfort Care For Animals Llc |
Liposome loading
|
WO2016197132A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Treating hepatitis b virus infection using crispr
|
WO2017019891A2
(en)
|
2015-07-29 |
2017-02-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing hepatitis b virus gene expression
|
US10429302B2
(en)
|
2015-08-11 |
2019-10-01 |
Scintillon Institute For Biomedical And Bioenergy Research |
Optical analyses of particles and vesicles
|
US10363226B2
(en)
|
2015-08-12 |
2019-07-30 |
North Carolina State University |
Platelet membrane-coated drug delivery system
|
CA3010711A1
(en)
|
2016-01-08 |
2017-07-13 |
The Regents Of The University Of California |
Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
|
US10188749B2
(en)
|
2016-04-14 |
2019-01-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
CA3020857A1
(en)
|
2016-04-14 |
2017-10-19 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
EP3452108A4
(en)
|
2016-05-04 |
2019-12-25 |
Lantheus Medical Imaging, Inc. |
METHODS AND DEVICES FOR PREPARING ULTRASONIC CONTRAST AGENTS
|
CN109563511A
(zh)
|
2016-06-30 |
2019-04-02 |
阿布特斯生物制药公司 |
用于递送信使rna的组合物和方法
|
US9789210B1
(en)
|
2016-07-06 |
2017-10-17 |
Lantheus Medical Imaging, Inc. |
Methods for making ultrasound contrast agents
|
EP4371584A3
(en)
|
2016-12-21 |
2024-08-28 |
Fred Hutchinson Cancer Center |
Scaffolds to treat solid tumor cells and escape variants
|
JP7348063B2
(ja)
|
2017-01-05 |
2023-09-20 |
フレッド ハッチンソン キャンサー センター |
ワクチン効力を改善するためのシステム及び方法
|
WO2019118806A1
(en)
|
2017-12-14 |
2019-06-20 |
Solid Biosciences Inc. |
Non-viral production and delivery of genes
|
WO2020255062A1
(en)
|
2019-06-20 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
|
US20210023023A1
(en)
*
|
2019-07-25 |
2021-01-28 |
Vasayo, Llc |
Liposomal nutraceutical compositions and methods of making the same
|
WO2022133230A1
(en)
|
2020-12-18 |
2022-06-23 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
US11357727B1
(en)
|
2021-01-22 |
2022-06-14 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11278494B1
(en)
|
2021-01-22 |
2022-03-22 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11033495B1
(en)
|
2021-01-22 |
2021-06-15 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
EP4312536A1
(en)
|
2021-04-01 |
2024-02-07 |
Vestaron Corporation |
Liposome formulations for pesticide delivery and methods for producing and using the same
|
WO2023018990A2
(en)
|
2021-08-12 |
2023-02-16 |
Life Technologies Corporation |
Lipids for nucleic acid delivery
|
AU2023214198A1
(en)
|
2022-01-31 |
2024-08-15 |
Genevant Sciences Gmbh |
Ionizable cationic lipids for lipid nanoparticles
|
AU2023211981A1
(en)
|
2022-01-31 |
2024-08-15 |
Genevant Sciences Gmbh |
Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
NL2035417B1
(en)
|
2022-07-19 |
2024-07-30 |
Coty Inc |
Cosmetic composition
|
WO2024031051A1
(en)
|
2022-08-05 |
2024-02-08 |
Life Technologies Corporation |
Lipids for nucleic acid delivery
|
WO2024168010A2
(en)
|
2023-02-09 |
2024-08-15 |
Alnylam Pharmaceuticals, Inc. |
Reversir molecules and methods of use thereof
|